GLIMEPIRIDE tablet

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

GLIMEPIRIDE (UNII: 6KY687524K) (GLIMEPIRIDE - UNII:6KY687524K)

Available from:

NCS HealthCare of KY, Inc dba Vangard Labs

INN (International Name):

GLIMEPIRIDE

Composition:

GLIMEPIRIDE 1 mg

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [see Clinical Studies (14.1)].   Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.  Glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to : •    Glimepiride or any of the product's ingredients [see Warnings and Precautions (5.2) ]. Sulfonamide derivatives: Patients who have developed an allergic reaction to aulfonamide derivatives may develop an allergic reaction to glimepiride. Do not use glimepiride in patients who have a history of an allergic reaction to sulfonamide derivatives. Reported hypersensitivity reactions include cutaneous eruptions with or without pruritus as well as more serious reactions (e.g., anaphylaxis, angioedema, Stevens-Johnson Syndrome, dyspnea) [see Warnings and Precautions (5.2) and Adverse R

Product summary:

Glimepiride tablets, USP are available in the following strengths and package sizes: Glimepiride tablets USP, 1 mg are peach, oval, flat bevelled edged, uncoated tablets embossed “RDY” on one side and “320” separating “3” and “20” with bisect line scoring on the other side and are supplied in Blistercards of 30        NDC 0615-7523-39 Glimepiride tablets USP, 2 mg are green, oval, flat bevelled edged, uncoated tablets embossed “RDY” on one side and “321” separating “3” and “21” with bisect line scoring on the other side and are supplied in Blistercards of 30        NDC 0615-6576-39 Glimepiride tablets USP, 4 mg are blue, oval, flat bevelled edged, uncoated tablets embossed “RDY” on one side and “322” separating “3” and “22” with bisect line scoring on the other side and are supplied in Blistercards of 30        NDC 0615-6575-39 Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Dispense in well-closed containers with safety closures.

Authorization status:

Abbreviated New Drug Application

Summary of Product characteristics

GLIMEPIRIDE- GLIMEPIRIDE TABLET
NCS HEALTHCARE OF KY, INC DBA VANGARD LABS
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
GLIMEPIRIDE INFORMATION SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR GLIMEPIRIDE.
GLIMEPIRIDE TABLETS USP
INITIAL U.S. APPROVAL: 1995
INDICATIONS AND USAGE
Glimepiride tablets are a sulfonylurea indicated as an adjunct to diet
and exercise to improve glyemic control in adults with
type 2 diabetes mellitus (1.1). (1)
Important Limitations of Use: (1)
• Not for treating type 1 diabetes mellitus or diabetic ketoacidosis
(1.2). (1)
DOSAGE AND ADMINISTRATION
• Recommended starting dose is 1 or 2 mg once daily. Increase in 1
or 2 mg increments no more frequently than every
1 to 2 weeks based on glycemic response. Maximum recommended dose is 8
mg once daily (2.1). (2)
• Administer with breakfast or first meal of the day (2.1). (2)
• Use 1 mg starting dose and titrate slowly in patients at increased
risk for hypoglycemia (e.g., elderly patients with renal
impairment) (2.1). (2)
DOSAGE FORMS AND STRENGTHS
Tablets (scored): 1 mg, 2 mg, 4 mg (3) (3)
CONTRAINDICATIONS
• Hypersensitivity to glimepiride or any of the product's
ingredients (4) (4)
• Hypersensitivity to sulfonamide derivatives (4) (4)
WARNINGS AND PRECAUTIONS
• Hypoglycemia: May be severe. Ensure proper patient selection,
dosing, and instructions, particularly in at-risk
populations (e.g.,elderly, renally inpaired) and when used with other
anti-diabetic medications (5.1). (5)
• Hypersensitivity Reactions: Postmarketing reports inlude
anaphylaxis, angioedema and Stevens-Johnson Syndrome.
Promptly discontinue glimepiride, assess for other causes, institute
appropriate monitoring and treatment, and initiate
alternative treatment for diabetes (5.2). (5)
• Hemolytic Anemia: Can occur if glucose 6-phosphate dehydrogenase
(G6PD) deficient. Consider a non-sulfonylurea
alternative (5.3). (5)
• Potential Increased Risk of Cardiovascular Mortality wit